Journal of Medicinal Chemistry · 2004 · 92 citations · 7 references
PharmacyMedicinal ChemistryPharmacologyBiochemical PharmacologyDrug DesignDrug DiscoveryEnzyme InhibitionReceptor Tyrosine Kinase SignalingTyrosine Kinase InhibitorsAtp DependenceCellular ProliferationKinase InhibitorsPhysicochemical PropertiesProtein Kinase InhibitorsSubstituent Effects On Biological ActivityTyrosine Kinase InhibitionVegfr Inhibitors
The pyrrolo[2,1-f][1,2,4]triazine nucleus was identified as a novel kinase inhibitor template which effectively mimics the well-known quinazoline kinase inhibitor scaffold. Attachment of a 4-((3-chloro-4-fluorophenyl)amino) substituent to the template provided potent biochemical inhibitors of the tyrosine kinase activity of EGFR, as well as inhibition of cellular proliferation of the human colon tumor cell line DiFi. Attachment of a 4-((3-hydroxy-4-methylphenyl)amino) substituent provided potent inhibitors of VEGFR-2 which also showed effects on the VEGF-dependent proliferation of human umbilical vein endothelial cells. Biological activity was maintained with substitution at positions 5 or 6, but not 7, suggesting that the former positions are promising sites for introducing side chains which modulate physicochemical properties. Preliminary inhibition studies with varying ATP concentrations suggest that, like the quinazoline-based kinase inhibitors, the pyrrolotriazine-based inhibitors bind in the ATP pocket.
7
Andrew Barker, Keith H. Gibson, Walter Grundy et al. · Bioorganic & Medicinal Chemistry Letters · 2001 · 563 citations · Full text
Medicine, Oncology, Pharmacology +9
Laurent Hennequin, Elaine S. E. Stokes, Andrew P. Thomas et al. · Journal of Medicinal Chemistry · 2002 · 308 citations · Full text
Gordon W. Rewcastle, William A. Denny, Alexander J. Bridges et al. · Journal of Medicinal Chemistry · 1995 · 261 citations · Full text